IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3650
+0.0134 (3.81%)
At close: Aug 22, 2025, 4:00 PM
0.3650
0.00 (0.00%)
After-hours: Aug 22, 2025, 8:00 PM EDT
Company Description
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.
The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s.
Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders.
The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma, Inc.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Ram Mukunda |
Contact Details
Address: 10224 Falls Road Potomac, Maryland 20854 United States | |
| Phone | (301) 983-0998 |
| Website | igcpharma.com |
Stock Details
| Ticker Symbol | IGC |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001326205 |
| CUSIP Number | 45408X308 |
| ISIN Number | US45408X3089 |
| Employer ID | 20-2760393 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ram Mukunda | President, Chief Executive Officer and Director |
| Claudia Grimaldi | Vice President, Principal Financial Officer, Chief Compliance Officer and Non-Independent Director |
| Benysh Qureshi Esq., M.B.A. | Director of Operations |
| Rohit Goel CPA, M.B.A. | Senior Director of Accounting and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 18, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 28, 2025 | EFFECT | Notice of Effectiveness |
| Jul 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 27, 2025 | 10-K | Annual Report |
| Jun 17, 2025 | 8-K | Current Report |
| Feb 14, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |